ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2739

Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis

Maureen D. Mayes for the US Scleroderma GWAS Group1, Lara Bossini-Castillo for the Spanish Scleroderma Group2, Olga Gorlova3, Jose Ezequiel Martin4, Xiaodong Zhou1, Wei Chen5, Shervin Assassi1, Jun Ying5, John D. Reveille1, Peter K. Gregersen6, Annette T. Lee7, Maria Teruel8, Francisco David Carmona4, Bobby P.C. Koeleman9, Matthew A. Brown and the Immunochip Consortium10, Christopher P. Denton11, Murray Baron for the Canadian Scleroderma Research Group12, Jasper Broen13, T.R.D.J. Radstake13 and Javier Martin4, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 5Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, 6Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 7Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 8Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 9Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 10Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 11Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 12Rheumatology, Jewish General Hospital, Montreal, QC, Canada, 13Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Genetic Biomarkers, genetics, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously associated loci. 

Methods : We genotyped 1,959 SSc cases and 3,582 controls of European ancestry from the United States and Spain using the Immunochip custom array containing 196,524 SNP variants within 186 known autoimmune risk loci. Ten SNPs were then chosen for replication in 4,017 SSc cases and 5,935 controls from 6 additional populations of European ancestry from the US, Canada, Europe and the UK for a combined population of 5,876 SSc cases and 9,517 controls.

Results : As noted in the Table below, we identified and validated 4 novel SSc risk loci including DNASE1L3 at 3p14, SCHIP1 | IL12A at 3q25, ATG5 at 6q21 and TREH/DDX6 at 11q23. Remarkably, the association of the rs35677470 missense variant in the DNASE1L3 locus with the ACA+ subset of patients is the most significant non-HLA association with SSc revealed to date (p = 2.70×10-32 OR=2.00).  In addition, we further refined the area of association for the STAT4, IRF5/TNPO3 loci and related an observed peak of association in the PXK gene to the novel DNASE1L3 locus.

Conclusion : The DNASE1L3 association suggests that failure to clear apoptotic debris plays a role in SSc; that the IL12 pathway is key to SSc susceptibility; that autophagy (ATG5), previously unreported in SSc, may be an important mechanism; and that DDX6, which has been shown to regulate VEGF under hypoxic conditions may provide a clue to SSc vasculopathy.

Novel non-HLA loci associated with SSc and its subsets (p < 5x10-8) identified through Immunochip analysis.

Locus

SNP

Chr

Minor Allele

Comments

Phenotype

MAF

Cases/CTRLs

p-value

OR

DNASE1L3

rs35677470

3p14

A

Missense Arg>Cys

All SSc

0.088/0.062

1.20×10-15

1.43

lcSSc

0.099/0.062

5.82×10-21

1.6

ACA+

0.133/0.062

2.70×10-32

1.99

SCHIP1 | IL12A

rs77583790

 

3q25

A

Intergenic

All SSc

0.015/0.005

2.25×10-12

2.54

lcSSc

0.016/0.005

3.60×10-12

2.74

ACA+

0.016/0.005

2.24×10-8

2.61

ATG5

rs9373839

6q25

G

Intronic

All SSc

0.241/0.185

2.16×10-8

1.18

TREH/DDX6

rs7130875

11q23

G

Intergenic

All SSc

0.27/0.24

4.03×10-8

1.17

 


Disclosure:

M. D. Mayes for the US Scleroderma GWAS Group,
None;

L. Bossini-Castillo for the Spanish Scleroderma Group,
None;

O. Gorlova,
None;

J. E. Martin,
None;

X. Zhou,
None;

W. Chen,
None;

S. Assassi,
None;

J. Ying,
None;

J. D. Reveille,
None;

P. K. Gregersen,
None;

A. T. Lee,
None;

M. Teruel,
None;

F. D. Carmona,
None;

B. P. C. Koeleman,
None;

M. A. Brown and the Immunochip Consortium,
None;

C. P. Denton,
None;

M. Baron for the Canadian Scleroderma Research Group,
None;

J. Broen,
None;

T. R. D. J. Radstake,
None;

J. Martin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunochip-analysis-identifies-new-susceptibility-loci-for-systemic-sclerosis-implications-for-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology